Targeted Oncology presents Investigator Perspectives, a video series featuring key opinion leaders discussing how to approach and manage patients with different tumor types.
Targeting CD19 in Diffuse Large B-Cell Lymphoma: Treatment Updates
A key opinion leader provides an overview of emerging data for a promising CD-19 targeted therapy and discusses how it has impacted the treatment paradigm.
Read More
Investigational Therapy in Mantle Cell Lymphoma: KTE-X19 CAR T-Cell Therapy
Michael Wang, MD, reacts to recent data and the potential to treat patients with relapsed or refractory mantle cell lymphoma with KTE-X19, an investigational CAR T-cell therapy.
The Evolving Role of Tucatinib in HER2-Positive Metastatic Breast Cancer
A key opinion leader discusses how the role tucatinib is evolving in the management of HER2-positive metastatic breast cancer.
Radioiodine Refractory Differentiated Thyroid Carcinoma
A key opinion leader discusses the evolving treatment landscape for radioiodine refractory differentiated thyroid carcinoma, with special consideration of the phase 3 SELECT trial.
Role of Targeted Therapies in Advanced Cholangiocarcinoma
Saeed Sadeghi, MD, comments on the utilization of FGFR2 inhibitors as treatment for advanced cholangiocarcinoma.
Ground-Breaking Data from the Phase III ADAURA Trial
A primary researcher on the Phase III ADAURA trial provides an overview of the ground-breaking data for managing patients with EGFR-positive NSCLC (non–small cell lung cancer).
The Role of Targeted Therapies in Advanced Cholangiocarcinoma
A discussion on the development of targeted therapies for the management of advanced cholangiocarcinoma, with consideration of multiple ongoing trials with notable outcomes.
Role of Novel Subcutaneous Daratumumab in Multiple Myeloma
How the recent FDA approval of the subcutaneous formulation of daratumumab in multiple myeloma will affect patients and oncologists from practical and clinical standpoints.
Update on HER2-Targeted Therapy in Early Breast Cancer
Sara M. Tolaney, MD, MPH, discusses newer approaches to managing early stages of HER2+ breast cancer in both the neoadjuvant and adjuvant spaces.
Progress in the Treatment of Follicular Lymphoma
Follicular Lymphoma
MET Targeted Therapy for NSCLC
Lung Cancer
Optimal Sequencing in Later Lines of Therapy for mCRC
Colorectal Cancer
BTK Therapy for the Frontline Treatment of CLL
Chronic Lymphocytic Leukemia
The Potential Impact of Targeting BCMA in R/R Multiple Myeloma
Multiple Myeloma
Targeting CD38 in Patients With Relapsed/Refractory Multiple Myeloma
Targeting CD38 in Relapsed/Refractory Multiple Myeloma
Emerging Therapies for HER2-Positive Metastatic Breast Cancer
Breast Cancer
Novel Combination Advances in CLL
Addressing Unmet Needs in Acute and Chronic GvHD
Graft versus Host Disease
New Strategy for Unmet Need in Relapsed/Refractory DLBCL
Novel Maintenance Combination in Advanced Ovarian Cancer
Ovarian Cancer
Emerging Data in R/R DLBCL
Non-Hodgkin Lymphoma
New Approval for the Nonmetastatic CRPC Population
Prostate Cancer
New Outcomes in Acute Graft-versus-Host Disease
What`s New in Acute Graft-versus-Host Disease?
Advances in Steroid-Refractory Acute GVHD
Reducing Early Disease Progression in Follicular Lymphoma
Addressing Unmet Needs in HER2-Positive Metastatic Breast Cancer
Advances in Metastatic Castration-Sensitive Prostate Cancer
Daratumumab as Frontline Treatment for Multiple Myeloma